Small Cap Feast
Small Cap Feast – 23rd March 2017
Dish of the Day:
Duke Royalty—Schedule 1 update. Seeking re-admission to AIM today as a Rule 8 investing company. Raising £15m
Duke Royalty—Schedule 1 update. Seeking re-admission to AIM today as a Rule 8 investing company. Raising £15m
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC.
Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April.
Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO.
BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Produce Investments (PIL.L) 202.5p £52.86m
H1Dec16 results from the operator in the fresh potato and daffodil sector. Board significantly strengthened with appointment of new Chairman, Group Finance Director and Non-Executive directors. Revenue £79.3m, up 1.0%. Operating profit £0.2m (2015: £3.4m) as result mainly of lag in raw material price recovery, and costs associated with the new ERP system. Interim dividend increased by 2% to 2.44p. Net debt £29.1m (2015: £22.8m). New “Acquire, Develop, Manage the Portfolio” strategy for future growth formulated and ready for implementation. “Current trading is well ahead of last year as we begin to recover higher raw material costs through our pricing arrangements with key customers.” FYJun16 Underlying trading profit broadly in line with the Board’s original expectations, however full year PBT will be lower than these expectations as a result of the non-cash write-offs. FYJun16E rev £185.1m and £8.1m PBT.
Gfinity (GFIN.L) 15.38p £24.2m
The eSports business, announces OMEN by HP as its first official partner of the inaugural eSports tournament, Gfinity Elite Series (“Elite Series”). As the Official Hardware Partner, OMEN will be integrated throughout the 10-week professional season which commences in June 2017, together with the supporting Gfinity Challenger competition. This announcement follows on from the agreement signed in August 2016, with HP Inc Limited, for an OMEN sponsored tournament, which took place at EGX, the UK’s largest gaming exhibition in September 2016. There are no market forecasts.
Solid State (SOLI.L) 512.5p £43.3m
The supplier of specialist industrial/ruggedised computers, electronic components, advanced antenna products, communications systems and battery power solutions to the electronics market, announces a trading update for the year ending 31 March 2017. Underlying PBT is expected to be broadly in line with expectations, being in excess of £3.1m with revenue in excess of £39m. The final quarter has seen a number of projects within the higher margin antenna division being delayed, consequently contribution from these projects is expected in future periods. The other areas of the manufacturing business unit have performed broadly in line with management’s expectations and the distribution business has performed slightly ahead of management’s expectations. The Group’s order book stood at £18.13m as at 28 February 2017 (29 February 2016: £16.45m). FYMar17E rev of £43.6m and £3.25m PBT.
Curtis Banks Group (CBP.L) 265p £142m
FYDec16 results from one of the UK’s leading SIPP providers with a portfolio of over 72,000 SIPPs. Operating revenue £29.7m from £17m. Underlying PBT £7.1m from £6m. 86% growth in SIPP numbers, 16% gross from organic growth. £27m raised in equity placing . Acquisition of Suffolk Life from Legal & General for £45m – completed 25 May 2016. “The outlook for 2017 is strong. We continue to be approached by SIPP operators looking for an exit for a variety of reasons and we evaluate opportunities as they come to us. We will only consider acquisitions of high quality books of SIPPs where we have confidence that they can provide at least the required level of operating margins. Admission to AIM has provided us with the resources and ability to consider and fund all levels of acquisition.” FYDec17E £38.89m and 14.73pEPS.
Craneware (CRW.L) 1192p £321.5m
The specialist Value Cycle solutions for the US healthcare market, announced a significant new contract with a large hospital operator in the US. This win, with an existing customer, adds further Value Cycle solutions and related services to a seven year contract originally announced in April 2014. The contract is expected to deliver a further $3.7m of revenue over this new seven year term as the hospital network rolls out these additional solutions across its facilities and $1.5m of additional revenue as the contract for the currently implemented solutions is extended to run co-terminus to this amendment. FYJun17E rev £47/07m and £14.07m PBT.
Ideagen (IDEA.L) 70.5p £128.7m
The supplier of Information Management Software to highly regulated industries, has acquired PleaseTech for an initial net consideration of £10m (on a cash-free, debt-free basis) and a potential further consideration of up to £2m dependent on the attainment of specified performance targets in the six months after completion. £10m placing at 75p. PleaseTech is a fast growing, profitable and cash generative software company. PleaseTech achieved revenue of £3.9m and EBITDA of £1.3m for FYDec16, an increase in revenue of 45% and EBITDA of 72%. Expected to enhance FYApr18 earnings. (FY18E EPS 3.9p).
Science In Sport (SIS.L) 82p £35.57m
FYDec16 results from the sports nutrition company that develops, manufactures and markets sports nutrition products for professional athletes and sports enthusiasts. Revenues increased by 30% to £12.24 million. Underlying operating loss of £0.8 million (2015: £0.25 million) in line with expectations and growth strategy, reflecting continued investment in brand awareness, e-commerce and International expansion. “Strong start to 2017 sales, core UK and EU market forecast to be EBITDA positive this year.” FYDec17E £15m rev and £1.19 PBT loss.
Progility (PGY.L) 1.13p £2.25m
HYDec16 results from Professional Services, Healthcare and Communications firm. Revenues up to £36.5 million (2015: £30.0 million). Operating profit £1.6 million (2015: £0.1 million). Comms and healthcare performing well with trading tougher in professional services. Benefitted from Sterling weakness. “Overall, we continue to pursue our strategic objectives, and we remain optimistic for the full year to June 2017. Management will continue to seek means to reduce costs and increase revenue, and to improve performance across all areas of the business.” There are no forecasts in the market.
Vela Technologies (VELA.L) 0.2p £1.44m
The investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement released on 22 March 2017 by BTL Group Ltd regarding a proposed fundraising by the company. Vela currently holds 689,800 common shares in BTL equivalent to c. 4% of BTL’s issued share capital. Vela intends to subscribe for 50,000 BTL Units in the BTL Fundraise for a total consideration of C$135,000. BTL intends to use the proceeds from the Private Placement in connection with acceleration of the development of Interbit, BTL’s proprietary blockchain platform and towards general and administrative expenses.
Venture Life Group (VLG.L) 68p £25.05m
FY Dec16 results from the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population. Revenues up 57% to £14.3 million. Adjusted EBITDA profit of £0.8 million (2015: loss of £0.6 million). Adjusted loss per share of 1.3p (2015: loss 3.1p). £2m cash. ‘We moved into January 2017 with a significantly higher order book for that month than January 2016, and with many discussions ongoing for new business across all of the Group’. FYDec17E £16,5m rev and £0.5m PBT.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.